Zirabev Injection, Solution
Product Images NDC 0069-0342

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Zirabev (NDC 0069-0342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Zirabev 01)

This is a chart showing the proportion of patients surviving after treatment with different medications for an unknown condition. The medications are referred to as IFL+ Placabo and IFL+ bevacizumab. The chart also displays the number of patients who received each treatment, as well as the duration of survival in months.*

FDA Label Image

Figure 2 (Zirabev 02)

This appears to be a table with data on survival rates in a medical study involving chemotherapy and the drug bevacizumab. The table contains information on the number of patients surviving in each month of the study, broken down by treatment group (chemotherapy alone or chemotherapy + bevacizumab). It is unclear what the units of measurement are for the "Proportion Surviving" column, and there is no additional context provided to interpret the findings.*

FDA Label Image

Figure 3 (Zirabev 03)

FDA Label Image

Figure 4 (Zirabev 04)

FDA Label Image

Figure 5 (Zirabev 05)

The text appears to be a table illustrating the proportion of overall survival between two groups, one group that received chemotherapy alone (n=225), and another group that received chemotherapy along with bevacizumab (n=227). The table shows the overall survival in months and the number of individuals at risk at different time intervals.*

FDA Label Image

Figure 6 (Zirabev 06)

FDA Label Image

Figure 7 (Zirabev 07)

FDA Label Image

Figure 8 (Zirabev 08)

FDA Label Image

Figure 9 (Zirabev 09)

FDA Label Image

Logo (Zirabev 10)

FDA Label Image

Principal Display Panel (4 mL Vial Label)

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Zirabev is an injection used for intravenous infusion after dilution that comes in a single-dose vial containing 100 mg/4 mL (25 mg/mL) of bevaczumab-bvr. The product should be stored at 2-8°C (6°F to &°F) and discarded after use. The solution contains a preservative, disodium edetate, polysorbate 80, succinic acid, sucrose, and water for injection. Dosage and administration must be done by a medical professional.*

FDA Label Image

Principal Display Panel (16 mL Vial Label)

This is a product label for the drug bevacizumab-bvzr, with dosage and administration instructions for intravenous infusion after dilution. It is supplied in a single-dose vial containing 400mg/16 mL, to be stored refrigerated at 2°C to 8°C in the original carton, protected from light. The drug is manufactured by Pfizer Inc. No further information is available.*

FDA Label Image

Principal Display Panel (16 mL Vial Carton)

The text is a description of a pharmaceutical product called Zirabev, which is for intravenous infusion and contains bevacizumab-bvzr. The product comes in a single-dose vial and should be discarded if unused. It is stored in a carton between 2 and 8 degrees Celsius. The text also provides information on the contents of each carton, indicating that it contains a preservative-free solution of bevacizumab-bvzr at a concentration of 40mg/25mL and instructions on how to handle the product.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.